---
title: "\"Profit Warning\" NT PHARMA reduces loss forecast, with a maximum loss of 30 million RMB last year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277052045.md"
description: "NT PHARMA issued a profit warning, expecting a net loss of between RMB 25 million and RMB 30 million for the fiscal year 2025, compared to a loss of RMB 53.4 million recorded in the previous year, a decrease of 43.8%-53.2%. The expected reduction in loss is mainly due to the recognition of a one-time non-cash fair value loss in the previous year and a fair value gain of RMB 14 million recorded in financial assets for this year"
datetime: "2026-02-26T13:43:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277052045.md)
  - [en](https://longbridge.com/en/news/277052045.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277052045.md)
---

# "Profit Warning" NT PHARMA reduces loss forecast, with a maximum loss of 30 million RMB last year

NT PHARMA (01011.HK) issued a profit warning, expecting a net loss of between RMB 25 million and RMB 30 million for the fiscal year 2025, compared to a loss of RMB 53.4 million recorded in the previous year, a decrease of 43.8%-53.2%. The expected reduction in loss is mainly due to the recognition of a one-time non-cash fair value loss in the previous year, and a fair value gain of RMB 14 million recorded in financial assets for this year

### Related Stocks

- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [01011.HK](https://longbridge.com/en/quote/01011.HK.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)

## Related News & Research

- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [China NT Pharma Says Director’s Judicial Records Tied to Settled Subsidiary Loan, No Material Impact Seen](https://longbridge.com/en/news/286577625.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Ontada Integrates Florida Cancer Specialists & Research Institute Data to Enrich Its Data Ecosystem](https://longbridge.com/en/news/287218916.md)
- [FDA approves FoundationOne CDx as TEPMETKO companion diagnostic in NSCLC](https://longbridge.com/en/news/287246470.md)